Literature DB >> 21277293

Thalassemia and hemoglobinopathies in Southeast Asian newborns: diagnostic assessment using capillary electrophoresis system.

Hataichanok Srivorakun1, Goonnapa Fucharoen, Yossombat Changtrakul, Patcharee Komwilaisak, Supan Fucharoen.   

Abstract

BACKGROUND: We have investigated the Capillarys 2 Hemoglobin testing system to assist in presumptive diagnosis of thalassemia and hemoglobinopathies commonly found in Southeast Asia.
METHODS: Study was conducted on 226 newborns. Hematological parameters were recorded and Hb profiles were examined on the Capillarys 2 Hemoglobin analyzer (SEBIA). DNA analyses were used to establish the final diagnoses.
RESULTS: Among 226 newborns examined, 122 had thalassemias with 17 different genotypes. The capillary electrophoresis system could provide useful data for presumptive diagnoses of cases, especially those with Hb E and α-thalassemia. Hb E was found to be 2.6-6.2% in heterozygote whereas Hb Bart's were clearly observed in cases with compound heterozygous or homozygous α(+)-thalassemia and heterozygous α(0)-thalassemia. Hb H disease and other forms of α-thalassemia could be differentiated based on the presence of Hb Bart's and its percentage.
CONCLUSION: The capillary electrophoresis system is applicable to newborn screening for common forms of thalassemia in Southeast Asia.
Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21277293     DOI: 10.1016/j.clinbiochem.2011.01.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Implementation of newborn screening for hemoglobin h disease in mainland china.

Authors:  Xing-Mei Xie; Jian-Ying Zhou; Jian Li; Ru Li; Can Liao; Dong-Zhi Li
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-20       Impact factor: 0.900

2.  Prevalence of anemia and underlying iron status in naive antiretroviral therapy HIV-infected children with moderate immune suppression.

Authors:  Pope Kosalaraksa; Torsak Bunupuradah; Saphonn Vonthanak; Surapon Wiangnon; Rawiwan Hansudewechakul; Ung Vibol; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Jurai Wongsawat; Wicharn Luesomboon; Pagakrong Lumbiganon; Bunruan Sopa; Tanakorn Apornpong; Theshinee Chuenyam; David A Cooper; Kiat Ruxrungtham; Jintanat Ananworanich; Thanyawee Puthanakit
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-25       Impact factor: 2.205

3.  Wooden-Tip Electrospray Mass Spectrometry Characterization of Human Hemoglobin in Whole Blood Sample for Thalassemia Screening: A Pilot Study.

Authors:  Tingting Huang; Ting Huang; Yongyi Zou; Kang Xie; Yinqin Shen; Wen Zhang; Shuhui Huang; Yanqiu Liu; Bicheng Yang
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

4.  α0-thalassemia in affected fetuses with hemoglobin E-β0-thalassemia disease in a high-risk population in Thailand.

Authors:  Supawadee Yamsri; Simaporn Prommetta; Hataichanok Srivorakun; Wachiraporn Taweenan; Kanokwan Sanchaisuriya; Attawut Chaibunruang; Goonnapa Fucharoen; Supan Fucharoen
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

5.  Haematological and electrophoretic characterisation of β-thalassaemia in Yunnan province of Southwestern China.

Authors:  Jie Zhang; Jing He; Xiaoqin Mao; Xiaohong Zeng; Hong Chen; Jie Su; Baosheng Zhu
Journal:  BMJ Open       Date:  2017-01-31       Impact factor: 2.692

6.  Prevalence of Thalassemia among Newborns: A Re-visited after 20 Years of a Prevention and Control Program in Northeast Thailand.

Authors:  Attawut Chaibunruang; Kanda Sornkayasit; Mattanee Chewasateanchai; Peerayoot Sanugul; Goonnapa Fucharoen; Supan Fucharoen
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

7.  Prevalence of Alpha(α)-Thalassemia in Southeast Asia (2010-2020): A Meta-Analysis Involving 83,674 Subjects.

Authors:  Lucky Poh Wah Goh; Eric Tzyy Jiann Chong; Ping-Chin Lee
Journal:  Int J Environ Res Public Health       Date:  2020-10-09       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.